Switching from natalizumab to fingolimod: An observational study

Acta Neurologica Scandinavica

Volumn 128, Issue 2, 2013, Pages

  Sempere, A P ^a   Martin Medina P ^b   Berenguer Ruiz, L ^c   Perez Carmona N ^c   Sanchez Perez, R ^a   Polache Vengud, J ^a   Feliu Rey, E ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b MRI Unit   (Spain)

^c HOSPITAL MARINA BAIXA   (Spain)

Author keywords

Fingolimod; MRI; Multiple sclerosis; Natalizumab; Treatment

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; JC VIRUS; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT SAFETY; RELAPSE; SIDE EFFECT;

FINGOLIMOD; MRI; MULTIPLE SCLEROSIS; NATALIZUMAB; TREATMENT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; JC VIRUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880161793     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12082     Document Type: Note

References (14)

1. TYSABRI PML safety update. http://medinfo.biogenidec.com (accessed 08/20/2012).
2. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
3. Berger JR, Centonze D, Comi G et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010;68:409-11.
4. O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858-65.
5. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-91.
6. Killestein J, Vennegoor A, Strijbis EM et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010;68:392-5.
7. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010;68:395-9.
8. West TW, Killestein J, Fox RJ. Natalizumab discontinuation: an increasingly tricky proposition. Eur J Neurol 2012;19:663-4.
9. Borriello G, Prosperini L, Mancinelli C et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012;19:783-7.
10. Magraner MJ, Coret F, Navarre A et al. Pulsed steroid followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011;258:1805-11.
11. Havla J, Gerdes LA, Meinl I et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;58:1665-9.
12. Rossi S, Motta C, Studer V et al. Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2013;20:87-94.
13. Fox RJ, Kappos L, Cree B et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study. Mult Scler 2011;17:S509-10.
14. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-77.